Medical Information

Close attention should be paid to the safety of the heart, liver, and blood system during the treatment of Rabosinib. QT interval prolongation, hepatotoxicity, and bone marrow suppression are the three core risks, and standardized monitoring can effectively prevent serious adverse events.

1、 QT interval prolongation

1. Pre medication screening

Before starting treatment, an electrocardiogram examination must be completed to confirm that the QTc interval is less than 450 milliseconds. Simultaneously measure blood potassium and magnesium levels, and if they are below the normal range, correct them first.

2. Monitoring during medication use

The electrocardiogram needs to be rechecked every 2 weeks in the first cycle, and regular rechecks will be conducted according to clinical needs in subsequent cycles. If the QTc interval is prolonged to>480 milliseconds, medication should be suspended.

3. Avoid concomitant use of drugs that prolong QT interval

Avoid co administration with antiarrhythmic drugs, quinolone antibiotics, antipsychotic drugs, etc. When necessary, strengthen electrocardiogram monitoring.

2、 Hepatotoxicity

1. Pre medication evaluation

Before treatment, complete liver function tests (ALT, AST, total bilirubin, etc.) should be conducted to understand baseline levels.

2. Monitoring during treatment

The liver function will be rechecked every 2 weeks for the first 2 cycles, and then once a month thereafter. If ALT/AST levels increase to more than three times the upper limit of normal, medication should be suspended and close follow-up should be conducted.

3. Be alert to symptoms of liver injury

If symptoms such as worsening fatigue, yellowing of the skin and sclera, darkening of urine color, and upper right abdominal pain occur, immediate medical attention and liver function examination should be sought.

3、 Bone marrow suppression

1. Regular blood routine monitoring

Blood routine tests will be conducted every 2 weeks during the first treatment cycle, followed by monthly follow-up examinations. Focus on the levels of neutrophils, platelets, and hemoglobin.

2. Management of neutropenia

If the absolute value of neutrophils is below 1.0 × 10 ⁹/L, medication should be suspended according to medical advice. Pay attention to oral hygiene and avoid infection.

3. Attention to platelets and anemia

When the platelet count is below 50 × 10 ⁹/L or there is a clear tendency towards bleeding, medication should be discontinued. When anemia worsens and accompanied by fatigue and dizziness, promptly inform the doctor for evaluation.